Omrix Biopharma (NASDAQ:OMRI): Oppenheimer upgrades to Buy
I'm now hearing Oppenheimer is out with an upgrade on Omrix Biopharma (NASDAQ:OMRI), taking their rating to Buy from Hold saying they believe investors are overreacting to a revenue shortfall of roughly $8mm in IVIG sales to one customer, and would use any pullback in the share price as a buying opportunity.
Firm's tgt is $35.
Notablecalls: Nice move by OpCo! See below for further deets. I continue to see OMRI as actionable here.
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
